Skip to main content

28.01.2019 | Endocrine Tumors

A Population-Based Study on NIFTP Incidence and Survival: Is NIFTP Really a “Benign” Disease?

verfasst von: Antoine Eskander, MD, ScM, FRCS(C), Stephen F. Hall, MD, MSc, FRCS(C), Marosh Manduch, MD, FRCP(C), Rebecca Griffiths, BSc, Jonathan C. Irish, MD, MSc, FACS, FRCS(C)

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to determine the incidence of noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP) in Ontario, Canada and the predictors of disease-free survival (DFS) by comparing patients with follicular variant papillary thyroid cancer (FVPTC) and patients with NIFTP.

Methods

This population-based retrospective cohort study included all patients who had definitive surgery for well-differentiated thyroid cancer (WDTC) in Ontario, Canada between 1990 and 2001 and were followed until 2014. A conservative decision rule was applied to subtype-select FVPTCs into NIFTPs after pathology report review. The primary outcome was DFS, for which Cox proportional hazard regression analysis was performed to assess the impact of FVPTC versus NIFTP.

Results

At pathology re-review of the 725 FVPTC cases, 318 were reclassified as potential NIFTP. The median follow-up time was 15.3 years for the entire cohort and 15.9 years for those alive at the last follow-up visit. Disease failure occurred for 109 patients, 79 (19.4%) in the FVPTC group and 30 (9.4%) in the NIFTP group (p < 0.01). This effect was sustained in the multivariable analysis, with FVPTC showing significantly worse DFS than NIFTP (hazard ratio, 1.84; 95% confidence interval, 1.17–2.89). After recategorization of certain FVPTCs into NIFTPs, the findings showed that NIFTP accounted for 16.8% (1.461/8.699 per 100,000) of all WDTCs.

Conclusion

The disease failure rate for NIFTP was 9.4%. The NIFTP diagnosis is challenging for the pathologist and may make tumor behavior difficult to predict for this entity. Caution should be used in the management of patients with an NIFTP.
Literatur
1.
Zurück zum Zitat Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.CrossRefPubMed Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.CrossRefPubMed
2.
Zurück zum Zitat Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136:440–4.CrossRefPubMed Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136:440–4.CrossRefPubMed
3.
Zurück zum Zitat Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177:1357–61.CrossRefPubMedPubMedCentral Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177:1357–61.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–9.CrossRefPubMedPubMedCentral Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–9.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat McLaughlin JR, Kreiger N, Marrett LD, Holowaty EJ. Cancer incidence registration and trends in ontario. Eur J Cancer. 1991;27:1520–4.CrossRefPubMed McLaughlin JR, Kreiger N, Marrett LD, Holowaty EJ. Cancer incidence registration and trends in ontario. Eur J Cancer. 1991;27:1520–4.CrossRefPubMed
7.
Zurück zum Zitat Hall S, Schulze K, Groome P, Mackillop W, Holowaty E. Using cancer registry data for survival studies: The example of the Ontario Cancer Registry. J Clin Epidemiol. 2006;59:67–76.CrossRefPubMed Hall S, Schulze K, Groome P, Mackillop W, Holowaty E. Using cancer registry data for survival studies: The example of the Ontario Cancer Registry. J Clin Epidemiol. 2006;59:67–76.CrossRefPubMed
8.
Zurück zum Zitat Hall SF, Irish JC, Groome PA, Urbach DR. Practice patterns in the management of patients with differentiated thyroid cancer in Ontario Canada 2000–2008. J Otolaryngol Head Neck Surg. 2014;43:29.CrossRefPubMedPubMedCentral Hall SF, Irish JC, Groome PA, Urbach DR. Practice patterns in the management of patients with differentiated thyroid cancer in Ontario Canada 2000–2008. J Otolaryngol Head Neck Surg. 2014;43:29.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Hall SF, Irish J, Groome P, Griffiths R, Hurlbut D. Do lower-risk thyroid cancer patients who live in regions with more aggressive treatments have better outcomes? Thyroid. 2017;27:1246–57.CrossRefPubMed Hall SF, Irish J, Groome P, Griffiths R, Hurlbut D. Do lower-risk thyroid cancer patients who live in regions with more aggressive treatments have better outcomes? Thyroid. 2017;27:1246–57.CrossRefPubMed
10.
Zurück zum Zitat Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (eds). AJCC Cancer Staging Manual. 7th ed. Springer, New York. 2010. Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (eds). AJCC Cancer Staging Manual. 7th ed. Springer, New York. 2010.
11.
Zurück zum Zitat Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRefPubMed Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRefPubMed
12.
Zurück zum Zitat Lieffers JR, Baracos VE, Winget M, Fassbender K. A comparison of Charlson and Elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data. Cancer. 2011;117:1957–65.CrossRefPubMed Lieffers JR, Baracos VE, Winget M, Fassbender K. A comparison of Charlson and Elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data. Cancer. 2011;117:1957–65.CrossRefPubMed
13.
Zurück zum Zitat Sharabiani MT, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data. Med Care. 2012;50:1109–18.CrossRefPubMed Sharabiani MT, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data. Med Care. 2012;50:1109–18.CrossRefPubMed
14.
Zurück zum Zitat Xu B, Tallini G, Ghossein RA. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: historical context, diagnosis, and future challenges. Endocr Pathol. 2017;28:128–38.CrossRefPubMed Xu B, Tallini G, Ghossein RA. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: historical context, diagnosis, and future challenges. Endocr Pathol. 2017;28:128–38.CrossRefPubMed
15.
Zurück zum Zitat Xu B, Tallini G, Scognamiglio T, Roman BR, Tuttle RM, Ghossein RA. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27:512–7.CrossRefPubMedPubMedCentral Xu B, Tallini G, Scognamiglio T, Roman BR, Tuttle RM, Ghossein RA. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27:512–7.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Xu B, Farhat N, Barletta JA, et al. Should subcentimeter noninvasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category? Endocrine. 2018;59:143–50.CrossRefPubMed Xu B, Farhat N, Barletta JA, et al. Should subcentimeter noninvasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category? Endocrine. 2018;59:143–50.CrossRefPubMed
17.
Zurück zum Zitat Lloyd RV, Asa SL, LiVolsi VA, et al. The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Hum Pathol. 2018;74:1–4.CrossRefPubMed Lloyd RV, Asa SL, LiVolsi VA, et al. The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Hum Pathol. 2018;74:1–4.CrossRefPubMed
18.
Zurück zum Zitat Parente DN, Kluijfhout WP, Bongers PJ, et al. Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma: is NIFTP truly benign? World J Surg. 2018;42:321–6.CrossRefPubMed Parente DN, Kluijfhout WP, Bongers PJ, et al. Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma: is NIFTP truly benign? World J Surg. 2018;42:321–6.CrossRefPubMed
19.
Zurück zum Zitat Parente DN, Bongers PJ, Verzijl R, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): trading six for a risky half dozen: Reply. World J Surg. 2018;42:2279.CrossRefPubMed Parente DN, Bongers PJ, Verzijl R, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): trading six for a risky half dozen: Reply. World J Surg. 2018;42:2279.CrossRefPubMed
20.
Zurück zum Zitat Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol. 2017;30:810–25.CrossRefPubMed Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol. 2017;30:810–25.CrossRefPubMed
21.
Zurück zum Zitat Aburjania Z, Jang S, Montemayor-Garcia C, et al. Encapsulated follicular variant of papillary thyroid cancer: are these tumors really benign? J Surg Res. 2017;216:138–42.CrossRefPubMedPubMedCentral Aburjania Z, Jang S, Montemayor-Garcia C, et al. Encapsulated follicular variant of papillary thyroid cancer: are these tumors really benign? J Surg Res. 2017;216:138–42.CrossRefPubMedPubMedCentral
Metadaten
Titel
A Population-Based Study on NIFTP Incidence and Survival: Is NIFTP Really a “Benign” Disease?
verfasst von
Antoine Eskander, MD, ScM, FRCS(C)
Stephen F. Hall, MD, MSc, FRCS(C)
Marosh Manduch, MD, FRCP(C)
Rebecca Griffiths, BSc
Jonathan C. Irish, MD, MSc, FACS, FRCS(C)
Publikationsdatum
28.01.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07187-0

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.